§
Luxuse
Patent Intelligence
Sign In
Patent US2765949A successfully refreshed from Google Patents.
Patent US7553923B2 successfully refreshed from Google Patents.
← Back to Patent Explorer
US7553923B2 Active / In Force US ⏱️ 1.0 years remaining

Medical devices and applications of polyhydroxyalkanoate polymers

Assignee: Tepha Inc
•
Filing: 2007-10-26
•
Granted: 2009-06-30
•
Expires: 2027-10-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Devices formed of or including biocompatible polyhydroxyalkanoates are provided with controlled degradation rates, preferably less than one year under physiological conditions. Preferred devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws (including interference screws), bone plates and bone plating systems, surgical mesh, repair patches, slings, cardiovascular patches, orthopedic pins (including bone filling augmentation material), adhesion barriers, stents, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, atrial septal defect repair devices, pericardial patches, bulking and filling agents, vein valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion cages, skin substitutes, dural substitutes, bone graft substitutes, bone dowels, wound dressings, and hemostats. The polyhydroxyalkanoates can contain additives, be formed of mixtures of monomers or include pendant groups or modifications in their backbones, or can be chemically modified, all to alter the degradation rates. The polyhydroxyalkanoate compositions also provide favorable mechanical properties, biocompatibility, and degradation times within desirable time frames under physiological conditions.

Inventors

  • 👤 Simon F. Williams
  • 👤 David P. Martin
  • 👤 Frank A. Skraly

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 17:48
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/58; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61K; A61K31/00; A61K31/70; A61K31/715; A61L17/00; A61L17/06; A61L17/10; A61L17/12; A61L27/14; A61L27/18; A61L31/00; A61L31/04; A61L31/06; A61L31/14; A61L31/148; A61L31/16; C; C08; C08G; C08G63/00; C08G63/02; C08G63/06; C08J; C08J9/00; C08J9/26; C08K; C08K5/00; C08K5/0008; C08K5/0033; C08L; C08L67/00; C08L67/04; C12; C12P; C12P7/00; C12P7/62; C12P7/625; A61F2210/00; A61F2210/0004; A61L2300/00; C08J2201/00; C08J2201/04; C08J2201/044; C08J2201/0444; C08J2201/048; C08J2201/0482; C08J2367/00; C08J2367/04; Y; Y10; Y10S; Y10S606/00; Y10S606/907; Y10S606/911

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 80 words
A stent graft comprising a biodegradable polyhydroxyalkanoate composition that has a degradation rate under physiological conditions, wherein the degradation rate is controlled by addition of components to the polyhydroxyalkanoate composition, selection of the chemical composition of the polyhydroxyalkanoate, selection of the weight average molecular weight of the polyhydroxyalkanoate, selection of the processing conditions of the polyhydroxyalkanoate, or selection of the form of the composition, wherein the polyhydroxyalkanoate polymer has a weight average molecular weight of between 10,000 and 10,000,000 daltons.
Claim 2
Dependent Claim 80 words
A stent graft comprising a biodegradable polyhydroxyalkanoate composition that has a degradation rate under physiological conditions, wherein the degradation rate is controlled by addition of components to the polyhydroxyalkanoate composition, selection of the chemical composition of the polyhydroxyalkanoate, selection of the weight average molecular weight of the polyhydroxyalkanoate, selection of the processing conditions of the polyhydroxyalkanoate, or selection of the form of the composition, wherein the polyhydroxyalkanoate polymer has a weight average molecular weight of between 10,000 and 10,000,000 daltons.
Claim 3
Dependent Claim 15 words
The stent graft of claim 1 wherein the stent graft is supported by a stent.
Claim 4
Dependent Claim 11 words
The stent graft of claim 2 wherein the stent is absorbable.
Claim 5
Dependent Claim 12 words
The stent graft of claim 1 wherein the stent comprises a polyhydroxyalkanoate.
Claim 6
Dependent Claim 20 words
The stent graft of claim 2 wherein the stent graft further comprises a drug, growth factor and/or other active agent.
Claim 7
Dependent Claim 14 words
The stent graft of claim 2 wherein the stent is self expanding or balloon-expandable.
Claim 8
Dependent Claim 19 words
The stent graft of claims 2 wherein part or all of the stent graft or stent degrades over time.
Claim 9
Dependent Claim 17 words
The stent graft of claim 1 wherein the stent graft is used to treat a diseased vessel.
Claim 10
Dependent Claim 16 words
The stent graft of claim 8 wherein the diseased vessel comprises an aneurysm or plaque deposit.
Claim 11
Dependent Claim 21 words
The stent graft of claim 8 wherein the stent graft delivers a drug, growth factor or other active agent when deployed.

References Cited (Backward Citations)

US3598122B1 Cited
US3598123A Cited
US3797494A Cited
US3598122A Cited
US3731683A Cited
US3982543A Cited
US4031894A Cited
US4205399A Cited
US4201211A Cited
US4286592A Cited
US4314557A Cited
US4379454A Cited
US4849226A Cited
US4435180A Cited
US4537738A Cited
US4559222A Cited
US4910145A Cited
US4704282A Cited
US4588580B2 Cited
US4588580A Cited
US4588580B1 Cited
US4603070A Cited
US4573995A Cited
GB2166354B Cited
US4856188A Cited
US4648978A Cited
US4645502A Cited
JPS62209144A Cited
US4880592A Cited
US4826493A Cited
US4792336A Cited
US4758234A Cited
US4664655A Cited
US5032638A Cited
EP0258781A1 Cited
US4711241A Cited
US4908027A Cited
US4853226A Cited
US5334698A Cited
US4788062A Cited
US4816258A Cited
US5306286A Cited
US5512669A Cited
US5534432A Cited
US5245023A Cited
US5480794A Cited
US5250430A Cited
US4943435A Cited
EP0344704B1 Cited
EP0754467A1 Cited
EP0349505B1 Cited
JPH0523189Y2 Cited
US5834582A Cited
US5502158A Cited
US4938763A Cited
US4938763B1 Cited
US5278202A Cited
US5278201A Cited
US5085629A Cited
US5041100A Cited
US5002067A Cited
US5128144A Cited
EP0423484B1 Cited
EP0429403B1 Cited
US5271961A Cited
JPH03187386A Cited
EP0432443A1 Cited
DE3937649A1 Cited
US5124371A Cited
US5705187A Cited
EP0452111B1 Cited
US5171308A Cited
US5711933A Cited
JPH04292619A Cited
EP0507554B1 Cited
WO1992018164A1 Cited
JPH04326932A Cited
US5753708A Cited
US5648100A Cited
US5635215A Cited
US5236431A Cited
US5292860A Cited
WO1993005824A1 Cited
US5480394A Cited
US5551954A Cited
JPH05194141A Cited
US5876452A Cited
US5204382A Cited
US6878248B2 Cited
WO1993020134A1 Cited
US5703160A Cited
WO1994002184A1 Cited
US6214387B1 Cited
US5278256A Cited
WO1994006886A1 Cited
US5550173A Cited
US5646217A Cited
US5516883A Cited
EP0601885B1 Cited
US5443458A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2012-06-29 2012-12-29 2013-06-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2016-06-29 2016-12-29 2017-06-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2020-06-29 2020-12-29 2021-06-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag